SLC22A16 Polyklonaler Antikörper
SLC22A16 Polyklonal Antikörper für WB, IHC, IF/ICC, Indirect ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human
Anwendung
WB, IHC, IF/ICC, Indirect ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 26833-1-PBS
Synonyme
Geprüfte Anwendungen
Produktinformation
26833-1-PBS bindet in WB, IHC, IF/ICC, Indirect ELISA SLC22A16 und zeigt Reaktivität mit human
| Getestete Reaktivität | human |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Polyklonal |
| Typ | Antikörper |
| Immunogen | SLC22A16 fusion protein Ag25270 |
| Vollständiger Name | solute carrier family 22 (organic cation/carnitine transporter), member 16 |
| Berechnetes Molekulargewicht | 65 kDa |
| Beobachtetes Molekulargewicht | 68 kDa |
| GenBank-Zugangsnummer | BC047565 |
| Gene symbol | SLC22A16 |
| Gene ID (NCBI) | 85413 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Antigen-Affinitätsreinigung |
| Lagerungspuffer | PBS only |
| Lagerungsbedingungen | Store at -80°C. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
SLC22A16, also named as CT2, FLIPT2, or OCT6, belongs to the major facilitator (TC 2.A.1) superfamily and organic cation transporter (TC 2.A.1.19) family. SLC22A16 encodes an organic zwitterion transporter protein that transports carnitine and some anticancer drugs, including anthracyclines. As a carnitine transporter, SLC22A16 is involved in the regulation of fatty acid oxidation (FAO), which plays an important role also in the metabolic transformation of cancer cells. SLC22A16 expression in cancer cells is associated with increased sensitivity to the cytotoxic effects of doxorubicin. SLC22A16 has 3 isoforms with the molecular mass of 58, 61 and 65 kDa (PMID: 35761855, 35608746).











